Genomic Vision

First-Half 2023 Results - Seite 2

Financial structure at June 30, 2023

Genomic Vision had cash and cash equivalents of €14 thousand at 30^th June 2023, compared with €760 thousand at 30^th June 2022. This consumption of cash is directly linked to the company's current activities, in particular its labor cost.

The Company's short-term financial resources (Convertible notes with warrants, Research Tax Credit, Trade receivables) should enable it to finance its activities until end-October 2023. The Company is actively working on several financing and operational structuring options to rapidly secure the additional financial resources needed to pursue its development beyond this horizon. The Company anticipates a gradual extension of its 12-month financing horizon, in several stages: the materialization in the very short term of transactions on which it is actively working on, and which should enable it to strengthen its equity and thus pursue its activities during the year; then other complementary initiatives enabling it to extend its financial horizon to at least the end of 2024. On the basis of these factors, the Company's management has adopted the going concern assumption. However, there is no guarantee that the anticipated financing will be available.

Upcoming financial publication

• Revenue for the 3^rd Quarter of 2023: Tuesday, 14^th November 2023 (post market)

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services for the highly accurate characterization of genome modifications. We deliver high-quality integrated genomic analysis solutions to improve quality control and bioproduction standards of advanced gene therapies at scale. Based on molecular combing technology and artificial intelligence, The Company provides robust quantitative measurements needed for high confidence characterization of transformed cell lines and prediction of cell line performance, in particular in the context of the biomanufacturing processes of cell and gene therapies. Genomic Vision’s molecular combing technology has further applications in drug development of agents targeting DNA replication and damage response mechanisms, visualizing DNA replication kinetics and telomere length maintenance. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).